Following the introduction of the 13-valent pneumococcal conjugate vaccine in 2010, cases of PCV13-type invasive pneumococcal disease in New York City dropped among children younger than 5 years old, according to a study presented at the IDWeek meeting. Overall, the incidence of PCV13-type pneumococcal disease declined 82% from 2007 to 2012, mostly among children younger than 12 months of age. Another study presented at the same meeting found that PCV13 serotype disease was more prevalent among unvaccinated children in Ontario in the second year following the implementation of the vaccine.

Related Summaries